Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers

Clinical Pharmacology in Drug Development

Volumn 3, Issue 5, 2014, Pages 396-405

  Quartino, Angelica ^a   Huledal, Gunilla ^a   Sparve, Erik ^a,b   Lüttgen, Maria ^a   Bueters, Tjerk ^a   Karlsson, Pär ^a   Olsson, Tina ^c   Paraskos, Jonathan ^c   Maltby, Justine ^c   Claeson Bohnstedt, Kristina ^a   Lee, Chi Ming ^a   Alexander, Robert ^c   Fälting, Johanna ^a   Paulsson, Björn ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

BACE1 inhibitor; NONMEM; Pharmacokinetic pharmacodynamic; Population modeling; Translational

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AZD 3839; BETA SECRETASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; AZD3839; BACE1 PROTEIN, HUMAN; BIOLOGICAL MARKER; INDOLE DERIVATIVE; PEPTIDE FRAGMENT; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SECRETASE;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; EQUILIBRIUM CONSTANT; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; MOUSE; NONHUMAN; NORMAL HUMAN; PROTEIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DOWN REGULATION; DRUG ADMINISTRATION; ENGLAND; METABOLISM; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BIOMARKERS; COMPUTER SIMULATION; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INDOLES; LONDON; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 84904990947     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.130     Document Type: Article

References (35)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362:329-344.
2. Holtzman D, Morris JC, Goate AM, Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011; 3:77sr1.
3. Savonenko AV, Melnikova T, Hiatt A, et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacol Rev. 2012; 37:261-277.
4. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011; 377:1019-1031.
5. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010; 9:387-398.
6. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120:885-890.
7. Vassar R, Bennett BD, Babu-Khan S, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286: (5440):735-741.
8. Kimberly WT, Wolfe MS. Identity and function of γ-secretase. J Neurosci Res. 2003; 74:353-360.
9. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12:856-861.
10. Walsh DM, Selkoe DJ. Aβ oligomers-a decade of discovery. J Neurochem. 2007; 101:1172-1184.
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-356.
12. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256:184-185.
13. May PC, Dean A, Lowe SL, et al. Robust central reduction of amyloid-β in humans with orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011; 31:16507-16516.
14. Forman M, Tseng J, Palcza J, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration. ICAD Conf Abstr Alzheimer's Dement Suppl. 2012; 8(4):P704.
15. Lai R, Albala B, Kaplow JM, et al. First-in human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma β-amyloid levels after single dosing. ICAD Conf Abstr Alzheimer's Dement Suppl. 2012; 8(4):P96.
16. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007; 82:21-32.
17. Swahn B-M, Kolmodin K, Karlström S, et al. Design and synthesis of β-secretase (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem. 2012; 22:1854-1859.
18. Jeppsson F, Eketjäll S, Jansson J, et al. Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimer's disease. J Biol Chem. 2012; 287:41245-41257.
19. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokin Pharmacodyn. 2003; 30:387-404.
20. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13:143-151.
21. Lindbom L, Pihlgren P, Jonsson N, et al. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79:241-257.
22. Karlsson MO, Molnar V, Freijs A, et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos. 1999; 27:1220-1223.
23. Lu Y, Barton HA, Leung L, et al. Cerebrospinal fluid β-amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodegener Dis. 2012; doi: 10.1159/000341217
24. Lu Y, Riddell D, Hajos-Korcsok E, et al. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses. J Pharmacol Exp Ther. 2012; 342:366-375.
25. Lucas F. Novel BACE1 inhibitor, E2609, lowers Aβ levels in the cerebrospinal fluid and plasma in nonhuman primates. ICAD Conf Abstr Alzheimer's Dement Suppl. 2012; 8(4):P224.
26. Fukushima T. Novel BACE1 inhibitor, E2609, lowers Aβ levels in the brain, cerebrospinal fluid and plasma in rats and guinea pigs. ICAD Conf Abstr Alzheimer's Dement Suppl. 2012; 8(4):P223.
27. Niva C, Parkinson J, Olsson F, et al. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmcol. 2013; 69(6):1247-1260.
28. Willem M, Garratt AN, Novak B, et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science. 2006; 314:664-666.
29. Hu X, Caitlin WH, Wanxia H, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006; 9:1520-1525.
30. Kim DY, Gershbacher MT, Inquimbert P, et al. Reduced sodium channel Nav1.1 levels in Bace1-null mice. J Biol Chem. 2011; 286:8106-8116.
31. Cai J, Xiaoping Q, Kociok N, et al. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med. 2012; 4:980-991.
32. Cao L, Rickenbacher GT, Rodriguez S, et al. The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep. 2012; 2:231. doi: 10.1038/srep00231
33. McConlogue L, Buttini M, Anderson JP, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007; 282:26326-26334.
34. Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009; 29:10706-10714.
35. Aasa J, Hu Y, Eklund G, et al. Effects of solvents on the time dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes. Drug Metab Dispos. 2013; 41(1):159-169.